Press Releases
For Immediate Release
Gamma Pharmaceuticals "Goes for the Jugular," Converts Brand Royalty Arrangement to Joint Venture With Jugular, Inc., Improving Corporate Control and Balance Sheet
Las Vegas, Nevada, March 9, 2010 - Gamma Pharmaceuticals Inc. (OTC: GMPM)("Gamma" or the "Company") announced the formation of a joint venture company with Jugular, Inc. ("Jugular"), replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC ("Gamma Jugular") is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.
Peter Cunningham, Gamma's Chief Executive Officer, commented on the initiative, "Forming Gamma Jugular is important to the Company in two significant ways. First, we improve corporate control by integrating Gamma's infrastructure with Jugular, Inc. on our exclusive product range. Second, we eliminated a substantial debt obligation payable to Jugular per our Licensing Agreement from 2007. We believe this will provide management with additional flexibility in the future." Mr. Cunningham continued, "We have worked for two years developing our Jugular product line of energy products and high performance vitamins and nutriceuticals. The leading edge products we have developed achieved an 85% 'willingness to purchase' after the first try. Today, we are embarking on a national and global expansion, details of which we will release in the weeks ahead. We expect great things from the Gamma Jugular, 'Go for the Jugular' campaign."
On March 3rd 2010, Gamma announced that it has entered into a multi-year agreement with one of North America's leading wholesale distribution organizations to distribute the full line of Gamma products, which at full distribution equates to an annualized value of approximately $48.0 million. The Company will utilize a portion of the distribution arrangement to accelerate the rollout of the Gamma Jugular product range.
About Gamma Pharmaceuticals IncGamma Pharmaceuticals Inc., (www.gammapharma.com) is a marketing and product formulation company selling it’s own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma’s core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in Greater China and the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ children’s nutritional supplements featuring the call to action “Mom you’ve made a brilliant choice for you children’s nutrition;” SAVVY™ adult nutritional supplements featuring the call to action, “Be SAVVY Stay Healthhy;” and, Jugular Energy Products™ and high performance supplements featuring the call to action, “Go for the Jugular™.” Gamma’s customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma’s product sales and retail partners.
At present Gamma manufactures in North America, and distributes in the United States and China. Gamma’s products utilize proprietary “Gel Delivery Technology®”, to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU’s and holds licenses for 9 SKUs in China.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company’s stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: Gamma Pharmaceuticals Inc
Joe Cunningham (jcunningham@gammapharma.com)
Office: (702) 989 5262
Direct: (651) 204 2048